Enabling medical device vendors to realize the potential of the data collectible by their devices

Informations projet

bio-T

N° de convention de subvention: 888653

DOI

10.3030/888653

Projet clôturé

Date de signature de la CE 6 Novembre 2019

Date de début 1 Decembre 2019

Date de fin 29 Février 2020

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

SOFTIMIZE LTD
Israel

Periodic Reporting for period 1 - bio-T (Enabling medical device vendors to realize the potential of the data collectible by their devices)

Période du rapport: 2019-12-01 au 2020-02-29

Résumé du contexte et des objectifs généraux du projet

"The Internet of Medical Things (devices), a fast-growing multi-hundred billion dollar industry, is revolutionizing healthcare by enabling remote use of collected medical device data. BUT medical device manufacturers, eager to monetize on the data, face gaps in securing private patient data and designing remote care workflows. The involved risks (cyber, HIPAA/GDPR fines, cloud OPEX, usability, and time-to-market) lead vendors to turn to external solutions.
The device-agnostic bio-T remote clinical-care cloud platform, leveraging decades of technological IoT and cloud expertise of its founders, securely manages common yet complex remote care workflows. This ""undifferentiated heavy-lifting"" accelerates the transformation of medical device manufacturers from capital sales vendors into digital service providers while reducing their cyber, compliance and technological risks. bio-T is powering clients today, connecting thousands of FDA-cleared devices commercially, and accredited an ""AWS Advanced technology partner"".
The objectives of the bio-T project are focused on defining the technological, commercial and financial tasks to improve the platform’s performance from a technical perspective as well as ensuring that the platform meets and exceeds the basic requirements for adoption by IoMT stakeholders"

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

During the Feasibility Study, an in-depth study of the market was made to determine further market needs and the best go to market strategy. A detailed description of the next steps to follow to bring the innovation to commercialisation, such as: identification of activities and upgrades required to reach TRL9, work packages and budget preparation, definition of the full supply chain, definition of the business model and commercialisation strategy, risks and market analysis was made.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

In-house from-scratch development in medical device companies is our biggest competitor due to the relative ignorance about and the infancy of the IoMT platforms. However, their teams usually have very little experience in regulated cloud-native software and IoT. bio-T is ahead of the competition as they have both the expertise and market experience to cater to all the needs of Medtech manufacturers and vendors. bio-T is already powering FDA approved solutions and working on providing more functionality through adding deep device insights

Bio T logo